Selective PhotoTherapy.
Potent cancer drugs.
Activated only where needed.
Imagine activating cancer drugs only where needed.
We’re developing a therapy that targets tumors with unmatched precision, sparing healthy tissue.
For patients who now face disfiguring surgery — or have no treatment options at all.
At Lumox, we develop Selective PhotoTherapy: a new generation of targeted cancer therapy that combines:
Tumor-targeting nanobodies: Derived from llamas, nanobodies serve as targeting tools, guiding light-activatable drugs directly to cancer cells.
Light-activatable drugs: That can be controlled: when and where they are activated, and how cytotoxic they are.
Selective PhotoTherapy enables a simple but powerful principle:
We control when and where the drug is activated.
Lumox is proud to be an Utrecht University spin-off company, derived from the group of Associate Professor Sabrina Oliveira.
Our innovative therapy has undergone extensive validation in preclinical models and is currently undergoing successful experimentation in the veterinary clinic. The results are promising, showcasing robust antitumor activity coupled with a notable absence of side effects.
Head and Neck Cancer





Lumox B.V.
Address:
Princetonlaan 6, 3584 CB Utrecht, the Netherlands
Chamber of Commerce (KvK) number:
99056186